<DOC>
	<DOCNO>NCT02041611</DOCNO>
	<brief_summary>The primary goal study evaluate T cell immune status immune reconstitution association specific cytokine patient newly diagnose HGGs undergo standard RT/TMZ adjuvant TMZ .</brief_summary>
	<brief_title>Prospective Evaluation T-cell Immune Status Patients With Newly Diagnosed High Grade Gliomas</brief_title>
	<detailed_description>Numbers T-cell subtypes six time point patient newly diagnose HGGs undergo standard RT/TMZ adjuvant TMZ : 1 . Baseline within 2 week initiation RT/TMZ 2 . At end RT/TMZ approximately week 6 3 . Before adjuvant TMZ approximately week 10 4 . After 2 cycle TMZ approximately week 18 5 . After 4 cycle TMZ approximately week 26 6 . Three month last cycle TMZ Secondary Endpoints 1 . Changes serial T cell subtypes cytokine level 2 . Incidence lymphopenia relate infection 3 . Changes T-cell number subtypes TMZ administration 4 . Overall survival</detailed_description>
	<mesh_term>Glioma</mesh_term>
	<criteria>1 . Patients must least 18 year age . 2 . Patients must histologically confirm new diagnose high grade glioma pathology ( WHO grade III IV ) . 3 . Patients propose postoperative treatment plan must include standard radiation temozolomide . 4 . Patients must Karnofsky performance status â‰¥ 60 % ( i.e . patient must able care himself/herself occasional help others ) . 5 . Patients must able provide write informed consent . 6 . Steroid use allow . 1 . Patients HIV exclude .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>WHO grade III IV</keyword>
</DOC>